Lv4
449 积分 2022-07-13 加入
Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab
1天前
求助中
Safety and Efficacy of Avacopan in Patients with C3 Glomerulopathy Randomized, Double-Blind Clinical Trial
4天前
求助中
Safety and Efficacy of Avacopan in Patients with C3 Glomerulopathy: Randomized, Double-Blind Clinical Trial
4天前
已完结
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study
1个月前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
1个月前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
1个月前
已完结
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
2个月前
已完结
Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States
2个月前
已完结
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
2个月前
已完结
皖公网安备34019202002308
